Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Cash from Financing Activities came in at -$19000.0 in Q1 2026, up 90.82% YoY from -$9957.0 in Q1 2025, and down 100.23% on a QoQ basis from $8.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Cash from Financing Activities data on file, last reported at -$19000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 90.82% year-over-year to -$19000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (up 1731.52% YoY) and the FY2025 annual result came in at $17.8 million, up 1122.14% from the prior year.
- Cash from Financing Activities eased to -$19000.0 in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $97.8 million in Q4 2022 to a low of -$1.4 million in Q2 2023.
- A 5-year average of $6.4 million and a median of -$315000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 175.29% — and 2025, when it surged 4110.84%.
- Tracing DNA's Cash from Financing Activities over 5 years: stood at $97.8 million in 2022, then slumped by 100.65% to -$632000.0 in 2023, then jumped by 67.88% to -$203000.0 in 2024, then surged by 4110.84% to $8.1 million in 2025, then sank by 100.23% to -$19000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$19000.0 (Q1 2026), $8.1 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 16.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.49 Mn |
| Jun 30, 2026 | 16.49 Mn |
| Mar 31, 2026 | -19,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | 8.14 Mn |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | -98,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Mar 31, 2024 | -845,000.00 |